Clin2
NCT06067737Possibly a fitRecruiting

Psilocybin and buprenorphine for opioid use disorder

Opioid Use Disorder

Treatments studied

Part of Mental health clinical trials.

This study tests whether adding psilocybin (a psychedelic medicine) to buprenorphine (a medication for opioid use disorder) can help people stop using opioids and stay in recovery. It is for people who have already been on buprenorphine but are still using other opioids.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
90 people
Ages
21 years to 70 years
Study type
Interventional

Who can take part

  • You are between 21 and 70 years old.
  • You have been diagnosed with opioid use disorder.
  • You have taken buprenorphine before and are either starting it now, started it in the last 3 weeks, or are on it but still using other opioids.
  • You are not taking antidepressants or other medications that affect serotonin (like SSRIs or MAO inhibitors).
  • You have not used psychedelic drugs (like psilocybin, LSD) in the past year.
  • You have stable housing, can read and speak English, and are not at high risk for suicide.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06786325Recruiting· Phase 2
Psilocybin treatment study for opioid use disorder

This trial tests whether psilocybin can help people recovering from opioid use disorder while living at a residential treatment center. If you are already taking buprenorphine/naloxone (Suboxone), methadone, or have received Sublocade, this study may be an option for you.

Philadelphia, Pennsylvania
NCT06810310Recruiting· Phase 2
Psilocybin for motivation in opioid use disorder

This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) can help people with opioid use disorder stay motivated in recovery. It uses brain scans to see how psilocybin affects brain areas linked to motivation.

Philadelphia, Pennsylvania
NCT04161066Recruiting· Phase 1
Psilocybin plus buprenorphine to help opioid use disorder symptoms

This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.

Madison, Wisconsin
NCT06796062Recruiting· Phase 2
Psilocybin for opioid use disorder

This study tests whether psilocybin can help people who want to stop using opioids and are already in treatment. Eligible participants receive a single dose of psilocybin in a supervised setting and are followed to see if it reduces opioid use.

Albuquerque, New Mexico
NCT06160284Recruiting· Phase 1
Psilocybin for brain healing in opioid recovery

This study tests whether psilocybin, a psychedelic substance, can help change brain connections in people recovering from opioid use disorder. It involves brain scans and careful medical monitoring to explore new treatment options.

New Haven, Connecticut
NCT06608459Not yet recruiting· Phase 2
Psilocybin-assisted therapy for opioid use disorder trial

This study tests whether psilocybin (a compound found in certain mushrooms), given with therapy, can help people with moderate to severe opioid use disorder reduce their opioid use. Participants must have stable housing and a support person to join.

Hear when a new Opioid Use Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.